AR019807A1 - Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh - Google Patents

Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh

Info

Publication number
AR019807A1
AR019807A1 ARP980106619A ARP980106619A AR019807A1 AR 019807 A1 AR019807 A1 AR 019807A1 AR P980106619 A ARP980106619 A AR P980106619A AR P980106619 A ARP980106619 A AR P980106619A AR 019807 A1 AR019807 A1 AR 019807A1
Authority
AR
Argentina
Prior art keywords
insoluble
composition
insulin
prepare
compositions
Prior art date
Application number
ARP980106619A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR019807A1 publication Critical patent/AR019807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones insolubles que comprenden una proteína seleccionada entre insulina, análogos de insulina, y proinsulinas; una proteína derivatizadaseleccionada entre el grupo formado por insulina derivatizada, análogos de insulina derivatizada, y proinsulina derivatizada; un compuesto complejante; uncompuesto estabilizador de hexámero; y un cation de metal divalente. Formulaciones que incluyen dichas composiciones insolubles, de administracion parenteral yno parenteral para el tratamiento de estados de hiperglucemia y diabetes. La forma microcristalina del precipitado insoluble es farmacéuticamente análoga a laforma cristalina de la insulina protamina neutra Hagedorn (NPH) neutra. Las formulaciones en suspension de dichas composiciones insolubles poseen propiedadesde disolucion controlables que proporcionan una glucodinámica terapéuticamente ventajosa comparada con las formulaciones de insulina NPH.
ARP980106619A 1997-12-23 1998-12-22 Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh AR019807A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6860197P 1997-12-23 1997-12-23
US8885998P 1998-06-11 1998-06-11
US10994098P 1998-11-25 1998-11-25

Publications (1)

Publication Number Publication Date
AR019807A1 true AR019807A1 (es) 2002-03-20

Family

ID=27371371

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106619A AR019807A1 (es) 1997-12-23 1998-12-22 Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh

Country Status (24)

Country Link
US (2) US6531448B1 (es)
EP (1) EP0925792B1 (es)
JP (1) JP2001526225A (es)
KR (1) KR20010024799A (es)
CN (1) CN1284876A (es)
AR (1) AR019807A1 (es)
AT (1) ATE264690T1 (es)
AU (1) AU2008899A (es)
BR (1) BR9814471A (es)
CA (1) CA2315300A1 (es)
CO (1) CO4970787A1 (es)
DE (1) DE69823319D1 (es)
DZ (1) DZ2691A1 (es)
EA (1) EA003394B1 (es)
HR (1) HRP20000427A2 (es)
HU (1) HUP0100243A3 (es)
ID (1) ID25476A (es)
IL (1) IL136724A0 (es)
NO (1) NO20003269L (es)
NZ (1) NZ505091A (es)
PE (1) PE20000106A1 (es)
PL (1) PL341300A1 (es)
TR (1) TR200001935T2 (es)
WO (1) WO1999032116A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2452044A1 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US20050107441A1 (en) * 2001-12-21 2005-05-19 Kliewer Steven A. Compositions and methods for altering glucose production
DE60335797D1 (de) 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
BR0317888A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
EP1605967A1 (en) * 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
CA2518776A1 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
AU2014200247B2 (en) * 2004-07-19 2015-05-14 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP2626368B1 (en) * 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
PL373543A1 (pl) * 2005-03-10 2006-09-18 Instytut Biotechnologii i Antybiotyków Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
KR101067266B1 (ko) * 2005-08-29 2011-09-23 아지노모토 가부시키가이샤 영양 조성물
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
PT2074141T (pt) 2006-09-22 2016-11-10 Novo Nordisk As Análogos de insulina resistentes a proteases
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
BRPI0818004B8 (pt) * 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
PL2597103T3 (pl) 2007-11-16 2017-04-28 Novo Nordisk A/S Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
US20110034385A1 (en) * 2008-04-07 2011-02-10 National Institute Of Immunology Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
NZ588857A (en) * 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
CA2738615A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
BR112012014025A2 (pt) 2009-12-11 2017-01-31 Univ Case Western Reserve análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
EP2720711A1 (en) * 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
GB2513805B (en) * 2012-04-18 2020-04-01 Waters Technologies Corp Methods for quantifying polypeptides using mass spectrometry
BR112014026442A8 (pt) * 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2931301B2 (en) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
MX360420B (es) * 2012-12-19 2018-10-31 Wockhardt Ltd Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
BR112015017492A2 (pt) * 2013-01-22 2017-07-11 Univ Case Western Reserve análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira, método para diminuir o açúcar do sangue de um paciente, método para a preparação de análogos de insulina deficientes em resíduos b1-b3 e polipeptídio
CN103145829B (zh) * 2013-03-29 2015-06-03 江苏诺泰制药有限公司 一种地特胰岛素的纯化方法
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법
CN114306577B (zh) * 2020-10-10 2024-04-09 南京汉欣医药科技有限公司 一种门冬胰岛素30混悬液的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3012077A (en) * 1960-03-11 1961-12-05 Union Carbide Corp Process for the production of organo sulfur compounds
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
CA1174623A (en) 1981-09-15 1984-09-18 Finn H. Andresen Process for preparing human insulin or b-30 esters thereof
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
ATE93238T1 (de) 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
AT400337B (de) * 1990-05-02 1995-12-27 Plasser Bahnbaumasch Franz Gleisstopfmaschine mit in gleisquerrichtung verstellbaren stopfeinheiten
ATE176482T1 (de) 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
JP3014764B2 (ja) 1993-09-17 2000-02-28 ノボ ノルディスク アクティーゼルスカブ アシル化インスリン
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
DE69629210T2 (de) 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
ES2292189T3 (es) 1996-06-20 2008-03-01 Novo Nordisk A/S Preparaciones a base de insulina conteniendo manitol.
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3343129B2 (ja) 1997-02-07 2002-11-11 ノボ ノルディスク アクティーゼルスカブ タンパク質の結晶化
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose

Also Published As

Publication number Publication date
HUP0100243A3 (en) 2001-09-28
NO20003269L (no) 2000-08-23
KR20010024799A (ko) 2001-03-26
ATE264690T1 (de) 2004-05-15
EP0925792B1 (en) 2004-04-21
HUP0100243A2 (hu) 2001-08-28
CN1284876A (zh) 2001-02-21
US6531448B1 (en) 2003-03-11
EP0925792A2 (en) 1999-06-30
PE20000106A1 (es) 2000-02-09
PL341300A1 (en) 2001-04-09
DZ2691A1 (fr) 2003-03-29
BR9814471A (pt) 2000-10-10
JP2001526225A (ja) 2001-12-18
DE69823319D1 (de) 2004-05-27
EA003394B1 (ru) 2003-04-24
TR200001935T2 (tr) 2000-12-21
US20030144181A1 (en) 2003-07-31
CO4970787A1 (es) 2000-11-07
HRP20000427A2 (en) 2001-06-30
EP0925792A3 (en) 2001-09-12
IL136724A0 (en) 2001-06-14
WO1999032116A1 (en) 1999-07-01
ID25476A (id) 2000-10-05
NZ505091A (en) 2002-11-26
CA2315300A1 (en) 1999-07-01
NO20003269D0 (no) 2000-06-22
EA200000708A1 (ru) 2000-12-25
AU2008899A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
AR019807A1 (es) Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh
BR9813111A (pt) Composições de insulina insolúveis
ES2360505T3 (es) Preparados de insulina libre de zinc o con bajo contenido en cinc con estabilidad mejorada.
US8501440B2 (en) Fibrillation-resistant insulin and insulin analogues
JP3676573B2 (ja) 迅速な作用発現を示す新規インスリン誘導体
EP2041169B1 (de) Amidiertes insulin glargin
TR201815158T4 (tr) Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri.
FI95202C (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
NO167187B (no) Fremgangsmaate til fremstilling av et legemiddel.
US20030232748A1 (en) Novel formulations
BR9407508A (pt) Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
ES2917893T3 (es) Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
NZ514609A (en) Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
RU2010133233A (ru) Новые производные инсулина с сильно замедленным профилем время/действие
IL128274A (en) Long-acting drugs and pharmaceutical compositions comprising them
ES2180511T3 (es) Formulaciones monodispersas de analogos de insulina acilados hexamericos.
KR930009591A (ko) 트리-아르기닌 인슐린
UA49890C2 (uk) Водна інсулінова композиція, парентеральна фармацевтична композиція та спосіб поліпшення хімічної стабільності інсулінової композиції
HU203840B (en) Process for producing mixed cristals suspension and mixed cristals containing native insuline and basically modificated insuline and injectable composition contining them
KR950700326A (ko) 파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
Jørgensen et al. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs
BR9307687A (pt) Análogos de insulina
John Basal insulin analogues--A review of recent data on efficacy and safety
EP0911035A3 (en) Insoluble insulin compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure